the need for disease-modifying drugs in myelofibrosis
Published 1 year ago • 114 plays • Length 0:51Download video MP4
Download video MP3
Similar videos
-
0:52
the need to incorporate disease-modifying drugs in lower-risk mds
-
1:39
the need for disease-modifying therapies in mpns
-
3:23
novel drugs and treatment strategies for myelofibrosis
-
1:08
insights into disease-modifying agents being explored in mpns
-
2:51
bomedemstat for high-risk myelofibrosis
-
4:16
how are high risk and low risk mds defined? #mds
-
4:28
understanding myelodysplastic syndromes (mds)
-
6:36
mds: low-risk disease treatment options
-
3:22
phase i dose-escalation study of zelavespib in patients with relapsed myelofibrosis
-
1:39
treating patients with myelofibrosis who are intolerant to or develop resistance to jak inhibitors
-
2:04
state-of-the-art treatment for hr-mds
-
1:53
parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
-
3:16
new mpn clinical trials & drugs in 2021
-
2:43
novel therapies in the future of mds treatment
-
1:32
novel drug targets for mds
-
2:21
precision medicine for mds, what drugs for which patients?
-
1:52
cytoreductive therapy for patients with pv
-
3:29
novel drugs and targets in mds
-
4:16
novel therapies for mpns
-
1:17
exciting novel treatments being developed for mds
-
4:18
novel drugs in the r/r mm: imids
-
1:49
pid unmet needs: awareness, testing and diagnosis